Has HC Surgical Specialists Limited (Catalist:1B1) Stock’s Recent Performance Got Anything to Do With Its Financial Health?
HC Surgical Specialists’ (Catalist:1B1) stock is up by 4.6% over the past three months. We wonder if and what role the company’s financials play in that price change as a company’s long-term fundamentals usually dictate market outcomes. Specifically, we decided to study HC Surgical Specialists’ ROE in this article.
Return on equity or ROE is an important factor to be considered by a shareholder because it tells them how effectively their capital is being reinvested. Simply put, it is used to assess the profitability of a company in relation to its equity capital.
Return on Equity = Net Profit (from continuing operations) ÷ Shareholders’ Equity
So, based on the above formula, the ROE for HC Surgical Specialists is:
42% = S$8.8m ÷ S$21m (Based on the trailing twelve months to May 2025).
The ‘return’ is the profit over the last twelve months. Another way to think of that is that for every SGD1 worth of equity, the company was able to earn SGD0.42 in profit.
So far, we’ve learned that ROE is a measure of a company’s profitability. We now need to evaluate how much profit the company reinvests or “retains” for future growth which then gives us an idea about the growth potential of the company. Assuming all else is equal, companies that have both a higher return on equity and higher profit retention are usually the ones that have a higher growth rate when compared to companies that don’t have the same features.
To begin with, HC Surgical Specialists has a pretty high ROE which is interesting. Second, a comparison with the average ROE reported by the industry of 9.2% also doesn’t go unnoticed by us. For this reason, HC Surgical Specialists’ five year net income decline of 7.0% raises the question as to why the high ROE didn’t translate into earnings growth. Based on this, we feel that there might be other reasons which haven’t been discussed so far in this article that could be hampering the company’s growth. These include low earnings retention or poor allocation of capital.
With the industry earnings declining at a rate of 7.0% in the same period, we deduce that both the company and the industry are shrinking at the same rate.
Catalist:1B1 Past Earnings Growth November 24th 2025
Earnings growth is an important metric to consider when valuing a stock. What investors need to determine next is if the expected earnings growth, or the lack of it, is already built into the share price. By doing so, they will have an idea if the stock is headed into clear blue waters or if swampy waters await. If you’re wondering about HC Surgical Specialists”s valuation, check out this gauge of its price-to-earnings ratio, as compared to its industry.
With a high three-year median payout ratio of 61% (implying that 39% of the profits are retained), most of HC Surgical Specialists’ profits are being paid to shareholders, which explains the company’s shrinking earnings. With only a little being reinvested into the business, earnings growth would obviously be low or non-existent. To know the 3 risks we have identified for HC Surgical Specialists visit our risks dashboard for free.
In addition, HC Surgical Specialists has been paying dividends over a period of nine years suggesting that keeping up dividend payments is preferred by the management even though earnings have been in decline.
Overall, we feel that HC Surgical Specialists certainly does have some positive factors to consider. Although, we are disappointed to see a lack of growth in earnings even in spite of a high ROE. Bear in mind, the company reinvests a small portion of its profits, which means that investors aren’t reaping the benefits of the high rate of return. So far, we’ve only made a quick discussion around the company’s earnings growth. So it may be worth checking this freedetailed graph of HC Surgical Specialists’ past earnings, as well as revenue and cash flows to get a deeper insight into the company’s performance.
Have feedback on this article? Concerned about the content?Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
